Total Payments
$249,251
2024 Payments
$24,295
Companies
6
Transactions
40
Payment Breakdown by Category
Consulting$238,680 (95.8%)
Other$5,625 (2.3%)
Travel$3,283 (1.3%)
Food & Beverage$1,397 (0.6%)
Research$168.00 (0.1%)
Education$99.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $238,680 | 5 | 95.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,625 | 1 | 2.3% |
| Travel and Lodging | $3,283 | 13 | 1.3% |
| Food and Beverage | $1,397 | 19 | 0.6% |
| Unspecified | $168.00 | 1 | 0.1% |
| Education | $99.00 | 1 | 0.0% |
Payments by Type
General
$249,083
39 transactions
Research
$168.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie, Inc. | $210,000 | 1 | $0 (2017) |
| VERTEX PHARMACEUTICALS INCORPORATED | $28,074 | 25 | $0 (2024) |
| PFIZER INC. | $7,434 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,531 | 6 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $113.31 | 1 | $0 (2018) |
| Astellas Pharma US Inc | $99.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,295 | 21 | VERTEX PHARMACEUTICALS INCORPORATED ($16,818) |
| 2023 | $11,316 | 12 | Vertex Pharmaceuticals Incorporated ($11,256) |
| 2022 | $168.00 | 1 | Novartis Pharmaceuticals Corporation ($168.00) |
| 2020 | $99.00 | 1 | Astellas Pharma US Inc ($99.00) |
| 2019 | $3,259 | 3 | Novartis Pharmaceuticals Corporation ($3,259) |
| 2018 | $113.31 | 1 | Alexion Pharmaceuticals, Inc. ($113.31) |
| 2017 | $210,000 | 1 | AbbVie, Inc. ($210,000) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $43.84 | General |
| Category: Oncology | ||||||
| 10/02/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $6,720.00 | General |
| 06/20/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,035.00 | General |
| 06/20/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $76.90 | General |
| 06/20/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $67.37 | General |
| 06/20/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $63.43 | General |
| 06/20/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $43.50 | General |
| 06/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: HEMATOLOGY | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Travel and Lodging | In-kind items and services | $218.77 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $47.39 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Travel and Lodging | In-kind items and services | $37.81 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 06/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 05/31/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Travel and Lodging | In-kind items and services | $378.96 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 05/22/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $180.44 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $639.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $387.67 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $337.96 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $263.66 | General |
| Category: HEMATOLOGY | ||||||
| 02/22/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $52.09 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 08/23/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,875.00 | General |
| 08/23/2023 | Vertex Pharmaceuticals Incorporated | — | Travel and Lodging | In-kind items and services | $130.10 | General |
| 08/23/2023 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $46.47 | General |
| 07/13/2023 | Vertex Pharmaceuticals Incorporated | — | Travel and Lodging | In-kind items and services | $336.55 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $168.00 | 1 |
About James Labelle
James Labelle is a Pediatric Hematology-Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700060472.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, James Labelle has received a total of $249,251 in payments from pharmaceutical and medical device companies, with $24,295 received in 2024. These payments were reported across 40 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($238,680).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Chicago, IL
- Active Since 12/18/2007
- Last Updated 10/24/2022
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1700060472
Products in Payments
- OXBRYTA (Drug) $7,434
- CASGEVY (Biological) $811.57
- SOLIRIS (Drug) $113.31
- KYMRIAH (Drug) $59.85
- SCEMBLIX (Drug) $43.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Chicago
Alexis Thompson, Md, MD
Pediatric Hematology-Oncology — Payments: $1.6M
Pediatric Hematology-Oncology $1.6M
Sherif Badawy, Md, MD
Pediatric Hematology-Oncology — Payments: $207,866
Pediatric Hematology-Oncology $207,866
Dr. Loretta Li, M.d, M.D
Pediatric Hematology-Oncology — Payments: $187,559
Pediatric Hematology-Oncology $187,559
Susan Cohn
Pediatric Hematology-Oncology — Payments: $125,685
Pediatric Hematology-Oncology $125,685
Leonard Valentino, M.d, M.D
Pediatric Hematology-Oncology — Payments: $117,453
Pediatric Hematology-Oncology $117,453
Dr. Miriam Bornhorst, Md, MD
Pediatric Hematology-Oncology — Payments: $69,696
Pediatric Hematology-Oncology $69,696